Cardinal Health Expands Cancer Therapy Production Capacity

Cardinal Health is significantly increasing its production capacity for Actinium-225, a key component in novel cancer therapies. This expansion addresses the rising demand for these advanced treatments. The company's investment in its production facilities underscores a commitment to supporting the development and availability of innovative oncology solutions. By scaling up its capabilities, Cardinal Health aims to ensure a stable supply chain for critical radiopharmaceuticals, thereby facilitating broader access to potentially life-saving cancer treatments for patients worldwide.